TY - JOUR
T1 - Standard of care for viral haemorrhagic fevers (VHFs): a systematic review of clinical management guidelines for high-priority VHFs
AU - Rigby, Ishmeala
AU - Michelen, Melina
AU - Dagens, Andrew
AU - Cheng, Vincent
AU - Dahmash, Dania
AU - Harriss, Eli
AU - Webb, Eika
AU - Cai, Erhui
AU - Lipworth, Samuel
AU - Oti, Alexandra
AU - Balan, Valeria
AU - Piotrowski, Helen
AU - Nartowski, Robert
AU - Rojek, Amanda
AU - Groves, Helen
AU - Hart, Peter
AU - Cevik, Muge
AU - Bosa, Henry Kyobe
AU - Blumberg, Lucille
AU - Fletcher, Tom
AU - Horby, Peter W.
AU - Jacob, Shevin
AU - Sigfrid, Louise
PY - 2023/2/6
Y1 - 2023/2/6
N2 - The Sudan virus disease outbreak in Uganda in 2022 showed our vulnerability to viral haemorrhagic fevers (VHFs). Although there are regular outbreaks of VHFs with high morbidity and mortality, which disproportionally affect low-income settings, our understanding of how to treat them remains inadequate. In this systematic review, we aim to explore the availability, scope, standardisation, and quality of clinical management guidelines for VHFs. We identified 32 guidelines, 25 (78%) of which were low quality and did not have supporting evidence and eight (25%) of which had been produced or updated in the past 3 years. Guidance on supportive care and therapeutics had little detail and was sometimes contradictory. Guidelines based on uncertain evidence are a risk to patients, an ethical challenge for clinicians, and a challenge to implementing trials due to heterogeneous standards of care. We recommend a standard living guideline framework to improve the quality, scope, and applicability of guidelines. Furthermore, investments into trials should aim to identify optimal treatment strategies for VHFs and prioritise affordable and scalable interventions to improve outcomes globally.
AB - The Sudan virus disease outbreak in Uganda in 2022 showed our vulnerability to viral haemorrhagic fevers (VHFs). Although there are regular outbreaks of VHFs with high morbidity and mortality, which disproportionally affect low-income settings, our understanding of how to treat them remains inadequate. In this systematic review, we aim to explore the availability, scope, standardisation, and quality of clinical management guidelines for VHFs. We identified 32 guidelines, 25 (78%) of which were low quality and did not have supporting evidence and eight (25%) of which had been produced or updated in the past 3 years. Guidance on supportive care and therapeutics had little detail and was sometimes contradictory. Guidelines based on uncertain evidence are a risk to patients, an ethical challenge for clinicians, and a challenge to implementing trials due to heterogeneous standards of care. We recommend a standard living guideline framework to improve the quality, scope, and applicability of guidelines. Furthermore, investments into trials should aim to identify optimal treatment strategies for VHFs and prioritise affordable and scalable interventions to improve outcomes globally.
U2 - 10.1016/s1473-3099(22)00874-x
DO - 10.1016/s1473-3099(22)00874-x
M3 - Review article
SN - 1473-3099
VL - 23
SP - E240-E252
JO - The Lancet Infectious Diseases
JF - The Lancet Infectious Diseases
IS - 7
ER -